Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07015853 · ClinicalTrials.gov registry record · Phase 2
ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation
A Phase 2 study, sponsored by Stephen Shiao.
- Not yet
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT07015853: Clinical Trial Phase 2 study, sponsored by Stephen Shiao.
NCT07015853 is a Phase 2 study that has not yet begun recruiting, run by Stephen Shiao. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07015853, a Phase 2 study, has not yet begun recruiting, sponsored by Stephen Shiao.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
Open label, single-arm, prospective therapeutic trial. Pembrolizumab (MK-3475), 200 mg IV Q3W starting at C1D1/Week 1 for up to 2 years, until disease progression, or treatment intolerance. RT, 8 Gy x 3 fractions over 3 consecutive days at C1D8/Week 2; Axatilimab (SNDX-6352; INCA034176), 1 mg/kg, IV, Q2W starting 1 week post- RT C1D15/Week 3 until disease progression or treatment intolerance.
Interventions
- DRUG Pembrolizumab
- RADIATION Radiotherapy
- DRUG Axatilimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2026-06 |
| Est. Completion | 2033-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07015853
The ClinicalTrials.gov registry entry for NCT07015853 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stephen Shiao, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT07015853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07015853 about?
NCT07015853 is a clinical study titled "ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation". Open label, single-arm, prospective therapeutic trial. Pembrolizumab (MK-3475), 200 mg IV Q3W starting at C1D1/Week 1 for up to 2 years, until disease progression, or treatment intolerance. RT, 8 Gy x 3 fractions over 3 consecutive days at C1D8/Week 2; Axatilimab (SNDX-6352; INCA034176), 1 mg/kg, IV...
What is the current status of trial NCT07015853?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2026-06. Estimated completion is 2033-07.
What interventions are being tested in trial NCT07015853?
The interventions under investigation include: Pembrolizumab (DRUG), Radiotherapy (RADIATION), Axatilimab (DRUG).
Who is sponsoring clinical trial NCT07015853?
This trial is sponsored by Stephen Shiao, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.